Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tysabri natalizumab autoimmune data

BIIB said in an SEC filing that no confirmed cases of progressive multifocal leukoencephalopathy (PML) had been

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE